I wonder if it's just because it's the wrong sort of good news....

I wonder if it's just because it's the wrong sort of good news. The expectation is for 4 products submitted for FDA review this year. I don't really have doubts about that - it might be a bit delayed, but ACR has proven that it can submit products for review. So this one was expected, and didn't make me jump and want to buy more. It's why I'm holding, but it isn't a pleasant surprise or proof of something not already proven.

I'd like to see more of the "2 product launches with profit share and other payments to Acrux" that's expected in CY2021. That would be a readjustment. Also the "objective to be cash flow positive by end of 2022". Progress towards that objective as measured by revenue would be cool.

I'm probably missing lots though.